Genentech Inc - Company Profile
Powered by 
All the sales intelligence you need on Genentech Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Genentech Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Genentech Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Genentech Inc (Genentech), a subsidiary of Roche Holding AG, is a biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious and life-threatening diseases. It offers drugs in various therapeutic areas, including oncology, infectious disease, immunology, ophthalmology, neurology, metabolism, primary care, and specialty care. Genentech also offers patient support services such as co-pay programs, health insurance, and independent co-pay assistance, among others. The company's products are offered to patients with complex health conditions mainly in the US healthcare market. It operates a manufacturing facility in the US. Genentech is headquartered in South San Francisco, California, the US.
Headquarters
United States of America
Address
1 DNA Way, Mailstop 258A, San Francisco, California, 94080
Website
www.gene.com
Telephone
1 650 2251000
No of Employees
12,100
Industry
Pharmaceuticals and Healthcare
Genentech Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| - | - | - |
| Alectinib | Patient Support | Alecensa |
| Bevacizumab | Co-Pay Programs | Avastin |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In April, the company entered into a partnership with Damon Wayans and diaTribe to launch of All Eyes on DME. |
| 2026 | Plans/Strategy | In January, the company announced its plans to invest US$2 billion to establish a new manufacturing plant in Holly Springs, North Carolina, the US. |
| 2025 | Regulatory Approval | In December, the company received approval from the US FDA for Lunsumio VELO (mosunetuzumab-axgb) for the treatment of adults with relapsed or refractory follicular lymphoma. |
Competitor Comparison
| Key Parameters | Genentech Inc | Peak Bio Inc | Chimerix Inc | MediGene Inc | Nitto Denko Avecia Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | San Francisco | Pleasanton | Durham | San Diego | Milford |
| State/Province | California | California | North Carolina | California | Massachusetts |
| No. of Employees | 12,100 | - | 79 | - | - |
| Entity Type | Private | Private | Private | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Thomas Schinecker | Chairman | Executive Board | - | - |
| Ashley Magargee | Chief Executive Officer; Director | Executive Board | 2024 | - |
| Levi Garraway | Chief Medical Officer; Director; Executive Vice President; Head- Product Development | Executive Board | - | - |
| Aviv Regev | Director; Executive Vice President - Genentech Research and Early Development | Executive Board | - | - |
| Matteo Pietra | Chief Financial Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer